Abstract

Background: Hypertension is a major cause of clinical and preclinical damage to the kidneys, heart, and other body organs. Damage to these organs manifests as cardiovascular diseases, impaired renal disease, heart failure, stroke, etc. Cardiovascular diseases are the primary cause of death in the world. Objective: This study evaluated the antihypertensive effect of the co-administration of calcium and captopril on dexamethasone-induced hypertension in adult male Wistar rats on Systolic blood pressure, Histology of the kidney, Oxidative stress level in the kidney; Catalase (CAT), Glutathione (GSH) and Superoxide dismutase (SOD), Lipid peroxidation level in the kidney (malondialdehyde (MDA), Thyroid gland histology and Renal function: urea and creatinine. Methods: Twenty-five male Wistar rats weighing 160g-200g were randomly grouped into 5 groups of 5 rats each; control group A(distilled water only), test group B (0.5 mg/kg dexamethasone injection), test group  C (0.5 mg/kg dexamethasone injection and 150mg/kg calcium), test group D (0.5 mg/kg dexamethasone injection and 40mg/kg captopril tablet), test group E (0.5 mg/kg dexamethasone injection, 40mg/kg captopril tablet and 150 mg/kg of calcium after thirty minutes). Results: The combination of calcium and captopril resulted in the restoration of the kidney function loss as seen in the histology of the kidney and thyroid gland. While the administration of captopril only showed more effectiveness in the treatment of systolic blood pressure. Conclusion: These results showed that the combination of Calcium and Captopril may be used in the treatment of organ damaged by hypertension while Captopril is a potent antihypertensive.

Keywords

Hypertension, Calcium, Captopril, Systolic Blood Pressure, Renal Function, Antioxidant Enzymes,

Downloads

Download data is not yet available.

References

  1. M.E. Rubio-Ruiz, I. Pérez-Torres, M.E. Soto, G. Pastelín, V. Guarner-Lans Aging in blood vessels. Medicinal agents FOR systemic arterial hypertension in the elderly. Aging research reviews, 18, (2014) 132-147.
  2. Q. Jiang, Q. Zhang, T. Wang, Q. You, C. Liu, S. Cao, Prevalence and risk factors of hypertension among college freshmen in China. Scientific Reports, 11(1), (2021) 1-8.
  3. S.E. Kjeldsen, Hypertension and cardiovascular risk: General aspects. Pharmacological Research, 129, (2018) 95-99.
  4. C. Guerrero-García, A.F. Rubio-Guerra, Combination therapy in the treatment of hypertension. Drugs in context, 7, (2018) 212531.
  5. M. Jadhav, C. Yeola, G. Zope, A. Nabar Aliskiren, the first direct renin inhibitor for the treatment of hypertension: the path of its development. Journal of Postgraduate Medicine, 58(1), (2012) 32-38.
  6. S. Man, L. Yang, H. Xiang, G. Lu, Y. Wang, C. Liu, W. Gao, Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats. Biomedicine & Pharmacotherapy, 125, (2020) 109977.
  7. M. Hashemzadeh, S. Park, H. Ju, R. Movahed, A novel design of combining the angiotensin-converting enzyme (ACE) inhibitor captopril with the angiotensin receptor blocker (ARB) losartan using homo coupling via PEG diacid linker. Recent Patents on Cardiovascular Drug Discovery (Discontinued), 8(3), (2013) 221-225.
  8. L.M. Moreira, R.P. Araujo, F.P. Leonel, H.V. Machado, A.O. Teixeira, F.V. Santos, J.P. Lyon, The biological roles of calcium: nutrition, diseases, and analysis. Royal Society of Chemistry, (2015) 21-29.
  9. E.O. Erhirhie, N.E. Ekene, D.L Ajaghaku, Guidelines on dosage calculation and stock solution preparation in experimental animals' studies. Journal of Natural Sciences Research, 4(18), (2014) 100-106.
  10. Y. Zhang, K. D. Croft, T. A. Mori, C.G. Schyvens, K.U. McKenzie, J.A. Whitworth, The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. American journal of hypertension, 17(3), (2004) 260-265.
  11. S.L. Ong, J.J. Vickers, Y. Zhang, K.U. McKenzie, C.E. Walsh, J.A. Whitworth, Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clinical and experimental pharmacology & physiology, 34(5-6), (2007) 517-519.
  12. D.M. Valerino, J.J. Mccormack, Xanthine oxidase-mediated oxidation of epinephrine. Biochemical Pharmacology, 20(1), (1971) 47-55.
  13. J. Sedlak, R.H. Lindsay, Estimation of total protein bound and nonprotein sulfhydryl groups in tissues with Ellman's reagent. Anal of Biochemistry, 25, (1968) 192-205.
  14. D.J. Jollow, J.R. Mitchell, N. Zampaglione, J.R. Gillette, Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3, 4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology, 11(3), (1974) 151-169.
  15. A.K. Sinha, Colorimetric assay of catalase. Analytical Biochemistry, 47(2), (1972) 389-394.
  16. V. Ádám-Vizi, A. Seregi, Receptor independent stimulatory effect of noradrenaline on Na, K-ATPase in rat brain homogenate: Role of lipid peroxidation. Biochemical pharmacology, 31(13), (1982) 2231-2236.
  17. J.L. Tan, K. Thakur (2021) Systolic hypertension. StatPearls Publishing.
  18. I.F. Alexa, M. Ignat, R.F. Popovici, D. Timpu, E. Popovici, In vitro, controlled release of antihypertensive drugs intercalated into unmodified SBA-15 and MgO modified SBA-15 matrices. International journal of pharmaceutics, 436(1-2), (2012) 111-119.
  19. A. Puzserova, I. Bernatova, Blood pressure regulation in stress: focus on nitric oxide-dependent mechanisms. Physiological rvar, S., & Nasiri Amiri, F. (2017). Association of lipid peroxidation and antioxidant status with metabolic syndrome in Iranian healthy elderly women. Biomedical Reports, 7(4), (2016) 331-336.
  20. G.V. Naregal, B.B. Devaranavadagi, S.G. Patil, B.S. Aski, Elevation of oxidative stress and decline in endogenous antioxidant defense in elderly individuals with hypertension. Journal of clinical and diagnostic research JCDR, 11(7), (2017) BC09.
  21. Bakhtiari, K. Hajian-Tilaki, S. Omidvar, & F. Nasiri Amiri (2017). Association of lipid peroxidation and antioxidant status with metabolic syndrome in Iranian healthy elderly women. Biomedical Reports, 7(4), 331-336.
  22. W. Domej, K. Oettl, W. Renner, Oxidative stress and free radicals in COPD–implications and relevance for treatment research, 65, (2014) 1207-1224.
  23. O. M. Ighodaro, O.A. Akinloye, First-line defense antioxidants-superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defense grid. Alexandria journal of medicine, 54(4), (2018) 287-293.
  24. K.A. Ahmad, D. Yuan Yuan, W. Nawaz, H. Ze, C. X. Zhuo, B. Talal, D. Qilong, Antioxidant therapy for management of oxidative stress-induced hypertension. Free radical research, 51(4), (2017) 428-438.
  25. A.C. Webster, E. V. Nagler, R.L. Morton, P. Masson, Chronic kidney disease. The Lancet, 389(10075), (2017) 1238-1252.
  26. B.M.I. Cabral, S.N. Edding, J.P. Portocarrero, E.V. Lerma, Rhabdomyolysis. Disease-a-Month, 66(8), (2020) 101015.
  27. S. Pasala, J.B. Carmody, How to use serum creatinine, cystatin C, and GFR. Archives of Disease in Childhood-Education and Practice, 102(1), (2017) 37-43.
  28. S. Vadakedath, V. Kandi, Dialysis: a review of the mechanisms underlying complications in the management of chronic renal failure. Cureus, 9(8), (2017) e1603.
  29. J.A. Kellum, P. Romagnani, G. Ashuntantang, C. Ronco, A. Zarbock, H.J. Anders, Acute kidney injury. Nature reviews Disease primers, 7(1), (2021) 1-17.
  30. P. Sobczuk, C. Szczylik, C. Porta, A.M. Czarnecka, (2017). Renin angiotensin system deregulation as renal cancer risk factor. Oncology Letters, 14(5), 5059-5068.
  31. J.M. Wardlaw, C. Smith, M. Dichgans, Small vessel disease: mechanisms and clinical implications. The Lancet Neurology, 18(7), (2019) 684-696.
  32. Y. Ohn, Y. Kanno, T. Takenaka, Central blood pressure and chronic kidney disease. World journal of nephrology, 5(1), (2016) 90.
  33. W.C. Lee, H.Y. Wong, Y.Y. Chai, C.W. Shi, N. Amino, S. Kikuchi, S. H. Huang, Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? Biochemical and biophysical research communications, 425(4), (2012) 842-847.
  34. J. Jiang, J.P. Zheng, Y. Li, Z. Gan, Y. Jiang, D. Huang, Y. Ke, Differential contribution of endothelium-derived relaxing factors to vascular reactivity in conduit and resistance arteries from normotensive and hypertensive rats. Clinical and Experimental Hypertension, 38(4), (2016) 393-398.
  35. M. Udovcic, R.H. Pena, B. Patham, L. Tabatabai, A. Kansar Hypothyroidism and the heart. Methodist DeBakey Cardiovascular Journal, 13(2), (2017) 55.
  36. B. Afsar, R. Elsurer, The relationship between magnesium and ambulatory blood pressure, augmentation index, pulse wave velocity, total peripheral resistance, and cardiac output in essential hypertensive patients. Journal of the American Society of Hypertension, 8(1), (2014) 28-35.
  37. F. Vargas, I. Rodriguez-Gomez, P. Vargas-Tendero, E. Jimenez, M. Montiel, The renin–angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. Journal of Endocrinology, 213(1), (2012) 25-36.
  38. J.K. Huang, L. Ma, W.H. Song, B.Y. Lu, Y.B. Huang, H.M. Dong, R. Zhou, MALAT1 promotes the proliferation and invasion of thyroid cancer cells by regulating the expression of IQGAP1. Biomedicine & Pharmacotherapy, 83, (2016) 1-7.
  39. E. Lurbe, E. Agabiti-Rosei, J. K. Cruickshank, A. Dominiczak, S. Erdine, A. Hirth, A. Zanchetti 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. Journal of hypertension, 34(10), (2016) 1887-1920.
  40. F.D. Fuchs, P.K. Whelton, High blood pressure and cardiovascular disease. Hypertension, 75(2), (2020) 285-292.